Berkeley Lab researchers have developed a new family of nanocarriers, called «3HM,» that meets all the size and stability requirements for effectively delivering therapeutic drugs to the brain for the treatment of a deadly form of cancer known
as glioblastoma multiforme.
Dr Steve Pollard and his team are developing potential new treatments for the most common type of brain tumour in adults, known
as glioblastoma multiforme.
The research identifies a potential characteristic for predicting outcome in a deadly form of brain cancer known
as glioblastoma multiforme.
Not exact matches
Most people with
glioblastoma multiforme die within a year of diagnosis,
as standard treatments can not eradicate these tumours.
Glioblastoma multiforme (GBM), an aggressive brain tumor affecting both adults and children, has dismal outcomes
as well:
ISB's brain - related research spans across nine of our lab groups and covers such diseases
as Alzheimer's, ALS,
glioblastoma multiforme, bipolar disorder, and PTSD.
As part of the Cancer Genome Atlas (TCGA) consortium, we're working on
glioblastoma multiforme (brain cancer) and ovarian cancer.